ClinicalTrials.gg
Active, not recruitingNCT05881408ENVISIONUpdated May 22, 2026

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

A Phase 3 interventional study of delandistrogene moxeparvovec and placebo in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Active, not recruiting at 46 sites in 14 countries. Open to male participants. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Sarepta Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
148
Allocation
Randomized
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..

Planned enrollment
5th of 25
148 · median 24
Started
2023
with 1 other
Phase 3
7 of 27
1 open now
Registered
21st of 27
by date

Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 5th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2023, is one of 7 in phase 3, and was the 21st registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., or all of them as a file.
02

Study summary

The study will evaluate the safety and efficacy of delandistrogene moxeparvovec gene transfer therapy in non-ambulatory and ambulatory males with DMD. This is a randomized, double-blind, placebo-controlled 2-part study. Participants will be in the study for approximately 128 weeks. All participants will have the opportunity to receive intravenous (IV) delandistrogene moxeparvovec in either Part 1 or Part 2.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • DMD
  • Gene-Delivery
  • Pediatric
  • North Star Ambulatory Assessment (NSAA)
  • Performance of Upper Limb (PUL)
  • Duchenne
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Definitive diagnosis of DMD based on documented clinical findings and prior genetic testing.
  • Cohort 1 only: Non-ambulatory per protocol-specified criteria.
  • Cohort 2 only: Ambulatory per protocol-specified criteria and ≥8 to \<18 years of age at the time of Screening.
  • Ability to cooperate with motor assessment testing.
  • Stable daily dose of oral for at least 12 weeks prior to Screening, and the dose is expected to remain constant throughout the study (except for modifications to accommodate changes in weight).
  • Recombinant Adeno-Associated Virus Serotype rh74 (rAAVrh74) antibody titers are not elevated as per protocol-specified requirements.
  • A pathogenic frameshift mutation or premature stop codon in the DMD gene, except for any deletion mutations in exon 8 and/or 9.

Exclusion criteria

Exclusion Criteria:

  • Exposure to gene therapy, medication, or any treatment designed to increase dystrophin expression within protocol specified time limits.
  • Abnormality in protocol-specified diagnostic evaluations or laboratory tests.
  • Presence of any other illness, medical condition, or requirement for chronic drug treatment that in the opinion of the Investigator creates unnecessary risk for gene transfer.

Other inclusion or exclusion criteria could apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    Delandistrogene Moxeparvovec followed by Placebo

    Participants will receive single IV infusion of delandistrogene moxeparvovec on Day 1. Then, participants will receive a single IV infusion of matching placebo at approximately 72 weeks.

    Genetic: delandistrogene moxeparvovec · Genetic: placebo

  • Placebo comparator
    Placebo followed by Delandistrogene Moxeparvovec

    Participants will receive matching placebo IV infusion on Day 1. Then, participants will have the opportunity to receive a single IV infusion of delandistrogene moxeparvovec at approximately 72 weeks.

    Genetic: delandistrogene moxeparvovec · Genetic: placebo

Interventions

  • Geneticdelandistrogene moxeparvovec

    Single IV infusion of delandistrogene moxeparvovec

    Also known as: SRP-9001, delandistrogene moxeparvovec-rokl, ELEVIDYS

  • Geneticplacebo

    Single IV infusion of matching placebo

06

What researchers measure

Primary outcomes

  1. Part 1: Change From Baseline in the Total Score of Performance of Upper Limb (PUL) (Version 2.0) at Week 72

    Time frame: Baseline, Week 72

Secondary outcomes

  1. Part 1: Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 72

    Time frame: Baseline, Week 72

  2. Part 1: Change From Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Week 72

    Time frame: Baseline, Week 72

  3. Part 1: Quantity of Delandistrogene Moxeparvovec Dystrophin Expression at Week 12 as Measured by Western Blot

    Time frame: Week 12

  4. Part 1: Change From Baseline in Patient-Reported Outcomes Measurement Information (PROMIS) Score in Upper Extremity Function to Week 72

    Time frame: Baseline, Week 72

  5. Number of Participants with a Treatment Emergent Adverse Event (TEAE), Adverse Event of Special Interest (AESI), and Serious Adverse Event (SAE)

    Time frame: Baseline up to Week 124

  6. Part 1 (For Cohort 2 Only): Change From Baseline in the North Star Ambulatory Assessment (NSAA) Total Score at Week 72

    Time frame: Baseline, Week 72

  7. Part 1: Change From Baseline in Global Circumferential Strain as Measured by Cardiac MRI at Week 72

    Time frame: Baseline, Week 72

  8. Part 1: Change From Baseline in the Middle Domain Score of PUL (Version 2.0) at Week 72

    Time frame: Baseline, Week 72

07

Study locations

46 sites
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for May 2027, 48 months after the start.

Of 26 phase 3 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's planned 48 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2023
First posted
May 31, 2023
StartActual
May 31, 2023
Primary completionEst.
May 31, 2027
CompletionEst.
Jun 30, 2028
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05881408
Collaborators
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 31, 2023
Start date
May 31, 2023
Primary completion
May 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
May 22, 2026

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion